Why Cosentyx Needs Prior Authorization
Cosentyx (secukinumab) is an IL-17A inhibitor used for moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and a handful of other inflammatory conditions. It's also one of the more expensive maintenance biologics on the market. As of January 2026, the list price is roughly $8,492 per month for the self-injection pen or syringe and about $4,489 per infusion for the IV formulation — before any insurance, rebate, or assistance program is applied.
That price is exactly why every pharmacy benefit manager, including CVS Caremark, treats Cosentyx as a controlled-access specialty drug rather than something you can pick up at a retail counter without review. Prior authorization exists so Caremark's clinical team can confirm three things before paying for it: the diagnosis matches an FDA-approved use, the patient has been screened for tuberculosis (a required safety step for IL-17 biologics), and — on most plans — that less expensive treatments were tried first.
Why this matters: Cosentyx prior authorization isn't a one-time hurdle. Because it's a chronic maintenance therapy, the same review happens again at renewal, which is why understanding the criteria up front saves you from repeating the same paperwork fight every 12 months.
How CVS Caremark Reviews the Request
CVS Caremark is the pharmacy benefit manager for a large share of employer, union, Medicare Part D, and Medicaid managed care plans in the United States. When your insurance ID card routes through Caremark, every specialty drug request — including Cosentyx — is checked against a plan-specific clinical policy before the pharmacy claim can pay.
Your prescriber's office submits the request one of two ways: electronically through a portal like CoverMyMeds or Surescripts (the faster option), or by fax to the prior authorization line printed on your plan's PA form. A Caremark clinical reviewer — often a licensed pharmacist for straightforward cases, or a physician reviewer for anything requiring medical judgment — checks the submission against your plan's Cosentyx policy. If everything required is present and meets criteria, the system enters an approval and the pharmacy claim clears. If something is missing or doesn't meet criteria, the reviewer issues a denial with instructions on how to appeal.
Two details matter more than people expect. First, the exact criteria are set by your specific plan, not by Caremark globally — a Medicare Part D plan, an employer plan, and a Medicaid managed care plan using Caremark can have different step therapy rules for the same drug. Second, Caremark increasingly uses automated matching for select specialty medications, meaning a complete, well-documented request can clear in minutes rather than days. Cosentyx isn't yet on every plan's automated list, so don't assume speed — assume completeness.
Cosentyx PA Eligibility at a Glance
You're a strong candidate for first-pass Cosentyx approval if the following apply:
- You have a confirmed diagnosis of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or another FDA-approved indication for Cosentyx.
- Your chart documents a recent TB screening with a negative result, or an explanation if screening isn't current.
- You've already tried and had an inadequate response to, or have a documented intolerance or contraindication to, at least one conventional systemic therapy or biologic your plan considers "step one."
- Your prescriber is a dermatologist, rheumatologist, or another specialist familiar with documenting biologic therapy history.
- The prescribed dose and frequency match Cosentyx's FDA-approved dosing for your condition.
You're more likely to face a denial or delay if:
- The request only lists a diagnosis code with no history of prior treatments tried.
- There's no documented TB screening result anywhere in the submission.
- Your plan requires a specific step-one drug (often a TNF inhibitor) and your chart shows no trial of it, with no documented reason why.
- You're a new patient to the prescriber and records from a prior provider haven't been transferred yet.
- The request is for a dose or frequency that doesn't match Cosentyx's approved labeling for your condition.
Step Therapy: The Biggest Hurdle
Step therapy, sometimes called "fail first," is the single most common reason Cosentyx prior authorizations get denied on the first submission. Because Cosentyx belongs to a class of biologics (IL-17 and IL-23 inhibitors) that also includes Taltz, Skyrizi, and Tremfya, most Caremark-administered plans want to see that a patient tried a different, usually less expensive, class of biologic first — most often a TNF inhibitor such as Humira (adalimumab), Enbrel (etanercept), or their biosimilars.
What "documented" actually means: A chart note that just says "patient failed prior therapy" is usually not enough. Caremark reviewers generally want the name of the drug tried, the duration of the trial, and the specific reason it didn't work — inadequate response, a documented adverse reaction, or a medical contraindication that made the drug unsafe to try in the first place.
Step therapy requirements aren't universal, though. Some patients skip the step-therapy requirement entirely because of a documented contraindication to TNF inhibitors — for example, a history of demyelinating disease, certain heart failure diagnoses, or a prior serious infection linked to TNF inhibitor use. If any of those apply to you, make sure your prescriber's note says so explicitly rather than leaving the reviewer to infer it.
Cosentyx vs. Other IL-17/IL-23 Biologics on Caremark's Formulary
Cosentyx isn't the only biologic in its class, and knowing where it sits relative to its competitors helps explain why step therapy exists in the first place.
| Medication | Target | Typical Step Therapy Position | PA Documentation Focus |
|---|---|---|---|
| Cosentyx (secukinumab) | IL-17A | Usually requires prior TNF inhibitor trial | Prior therapy history, BSA affected, TB screening |
| Taltz (ixekizumab) | IL-17A | Usually requires prior TNF inhibitor trial | Nearly identical to Cosentyx; same drug class |
| Skyrizi (risankizumab) | IL-23 | Often preferred on newer specialty tiers; step position varies by plan | Diagnosis confirmation, prior biologic history if required |
| Tremfya (guselkumab) | IL-23 | Step position varies; some plans allow first-line use for PsA | Diagnosis confirmation, prior therapy if applicable |
Formulary position for this drug class shifts often as manufacturer rebate contracts change year to year, so the "preferred" biologic on your specific plan this year may not be the same one next year. If Cosentyx is denied and your prescriber is open to it, ask directly which biologic in this class is currently preferred on your plan's formulary — switching to the preferred option sometimes clears faster than appealing.
Documents Your Prescriber Needs to Submit
| Document | Why Caremark Wants It |
|---|---|
| Diagnosis confirmation with ICD-10 code | Confirms Cosentyx is being used for an FDA-approved indication |
| Chart notes on affected body surface area (psoriasis) or joint involvement (PsA/AS) | Establishes disease severity supports biologic therapy |
| Prior therapy history, including drug names, duration, and outcome | Satisfies step therapy requirements or documents why they don't apply |
| TB screening result (skin test or blood test) | Required safety screening before starting an IL-17 inhibitor |
| Current prescription with dose and frequency | Confirms the request matches FDA-approved dosing |
| Letter of medical necessity (if step therapy criteria aren't met) | Explains clinically why an exception to step therapy is appropriate |
How to Apply, Step by Step
Confirm your plan actually uses CVS Caremark
Check your insurance ID card or a recent explanation of benefits for the Caremark logo or "RxBIN" and "RxPCN" fields. If Caremark isn't listed, the prior authorization process and forms described here won't apply to your plan.
Ask your prescriber's office to pull your treatment history
Before submitting anything, your dermatologist or rheumatologist's office should gather records of every prior systemic treatment or biologic you've tried, including ones prescribed by a previous provider.
Get a current TB screening on file
If you haven't had a TB test within your plan's accepted window, schedule one before submitting. A missing or outdated TB result is one of the most common reasons a Cosentyx PA stalls.
Submit electronically when possible
Ask the prescriber's office to submit through CoverMyMeds or their EHR's built-in ePA tool rather than fax. Electronic submissions route directly into Caremark's review queue and are easier to track.
Have the office document exceptions clearly, if any apply
If you have a contraindication to the step-one drug your plan requires, make sure that's written into the submission in plain clinical language rather than assumed or left out.
Track the request and follow up
Most ePA portals show real-time status. If you haven't heard back within the standard turnaround window, call the number on your insurance ID card rather than waiting indefinitely.
Already have a Cosentyx prescription?
Ask your prescriber's office to submit the PA request electronically and confirm your TB screening is current before it goes in — that combination clears the most Cosentyx requests on the first try.
Caremark Prior Auth Info → See Required DocumentsDecision Tree: Will Your PA Be Approved?
Step 1: Does your plan use CVS Caremark as its pharmacy benefit manager?
✔ Yes → Continue to Step 2.
✖ No → This guide's specific process doesn't apply; check your plan's own PA process instead.
Step 2: Has your prescriber documented a trial of, or a contraindication to, a step-one biologic (usually a TNF inhibitor)?
✔ Yes → Continue to Step 3.
✖ No → Approval is unlikely on the first submission; ask your prescriber to either trial the step-one drug or document a clear contraindication.
Step 3: Is a current, negative TB screening result on file?
✔ Yes → You're a strong candidate — submit the request.
✖ No → Schedule TB screening first; most reviewers will pend or deny without it.
Approval Timelines
| Request Type | Typical Timeframe |
|---|---|
| Standard request, complete documentation | Within 72 hours of Caremark receiving everything needed |
| Urgent/expedited request | Within 24 hours on most plans; Medicare Part D plans follow this same standard |
| Request missing prior therapy documentation or TB result | Delayed until the prescriber's office provides additional information |
| Renewal request with updated clinical response notes | Typically similar to a new request — 72 hours once complete |
If your prescriber believes waiting the standard timeframe could seriously harm your health, they can request an expedited review. Not every situation qualifies as urgent, so this determination is made by the reviewer based on clinical information your prescriber provides, not simply because you'd prefer a faster answer.
What Happens After Approval
| Step | What Happens |
|---|---|
| Approval entered | Caremark enters the authorization; your prescriber's office is notified |
| Prescription routed | Most plans route Cosentyx through CVS Specialty Pharmacy for fulfillment |
| CareTeam outreach | A CVS Specialty CareTeam member calls to confirm delivery address and schedule |
| Shipment | Cosentyx ships in temperature-controlled packaging to your home or chosen address |
| Refills | CVS Specialty typically reaches out ahead of your next refill date |
Important: Cosentyx must stay refrigerated. Plan to be available to receive the package on the scheduled delivery day, and refrigerate it immediately — don't leave it sitting in a mailbox or on a porch.
For prescription status, refills, or delivery questions once you're routed to CVS Specialty, the general customer service line is 1-800-237-2767 (Monday–Friday, 8am–8pm ET). Billing questions go to 1-800-250-9631.
Renewing Your Authorization
Cosentyx authorizations through Caremark are typically approved in 12-month blocks. Because it's a maintenance biologic most patients stay on indefinitely, missing the renewal window can create a real gap in treatment — and for inflammatory conditions, gaps often mean symptoms creep back before the next shipment arrives.
- Start the renewal request before your current authorization expires, not after.
- Your prescriber needs to document ongoing clinical benefit — improved skin clearance, reduced joint pain, better mobility — not just restate the original diagnosis.
- If your dose changed during the year, make sure the renewal request reflects the current dose and frequency.
- Report any insurance changes right away; switching plans or PBMs can reset the authorization entirely.
If You're Denied: The Appeals Process
| Stage | What to Know |
|---|---|
| Denial letter | Sent to both you and your prescriber, with the specific reason for denial and appeal instructions |
| Filing window | You generally have 180 days from the denial letter to file an internal appeal |
| First-level internal appeal | Reviewed by a qualified reviewer with your supporting documentation; a decision and notification follow |
| Second-level internal appeal | Available on most plans if the first-level appeal is upheld |
| External review | An independent reviewer not affiliated with Caremark or your plan makes a final decision; this step overturns a meaningful share of specialty drug denials |
| Urgent appeal | Available for time-sensitive situations; decided faster than a standard appeal when your prescriber supports the urgency |
If you need to request an urgent review, call the number on your denial letter or the general CVS Caremark customer service line at 1-877-522-8679 for instructions. Don't skip the external review step if your internal appeals are denied — it's a genuinely different reviewer looking at the same evidence, and outcomes there are often better than patients expect.
Copay Card vs. Patient Assistance Foundation
Getting Cosentyx approved by Caremark and affording it are two separate problems. Novartis runs two very different programs depending on your insurance situation.
| Feature | Cosentyx Connect Copay Card | Novartis Patient Assistance Foundation |
|---|---|---|
| Who it's for | Patients with commercial (private) insurance | Uninsured or underinsured patients who meet income criteria |
| Cost to patient | As low as $0 per month, up to $16,000/year in support | $0 — free medication for eligible patients |
| Medicare/Medicaid eligible? | No — federal law excludes government-insured patients | Medicare patients: must show denial of Extra Help (LIS) first |
| Income limit | None — based on insurance type, not income | Based on household income and ability to pay |
| Where to apply | Cosentyx Connect portal or your prescriber's office | Novartis Patient Assistance Foundation directly |
Bottom line: If you have commercial insurance and Caremark approves your PA, the copay card is almost always the faster, simpler option. If you're uninsured or on Medicare without adequate coverage, the Patient Assistance Foundation is the path — call Novartis Patient Support at 1-844-267-3689 or the assistance line at 1-800-277-2254 to start.
Pros and Cons of the Caremark PA Process
Pros
- Standard decisions typically arrive within 72 hours once documentation is complete
- Electronic submission through CoverMyMeds is fast and trackable
- Clear appeal rights with a 180-day filing window and external review available
- CVS Specialty CareTeam support handles delivery logistics and refill reminders
- Novartis cost-assistance programs cover most income and insurance situations
Cons
- Step therapy often requires trying a TNF inhibitor first, which delays access to Cosentyx specifically
- Criteria vary by individual plan, so advice that worked for someone else's plan may not apply to yours
- Annual renewal repeats the same documentation burden every 12 months
- Cosentyx can't be picked up at a retail pharmacy counter once routed to specialty
- A missing TB screening or incomplete prior therapy history is a common, avoidable delay
Common Mistakes That Delay Approval
- Submitting a request with only a diagnosis code and no prior treatment history
- Leaving out TB screening results, or submitting outdated ones
- Assuming a contraindication to a step-one drug is obvious from the chart without stating it directly
- Faxing a request instead of using electronic submission when ePA is available
- Not confirming which biologic is currently preferred on your specific plan's formulary before submitting
- Waiting until the current authorization has already expired to start the renewal
The single biggest cause of delay for Cosentyx specifically is a prescriber note that reads like a generic biologic request instead of directly addressing step therapy — either by documenting the required trial or explaining clearly why it doesn't apply.
Real Patient Scenarios
Scenario: Plaque psoriasis patient who already tried Humira
A patient with moderate-to-severe plaque psoriasis used Humira for eight months with only partial improvement. Their dermatologist documents the drug name, duration, and inadequate response directly in the PA request. Because the step therapy requirement is clearly satisfied, the Cosentyx request clears on the first submission.
Scenario: Psoriatic arthritis patient with a TNF contraindication
A patient with psoriatic arthritis also has a history of demyelinating disease, which makes TNF inhibitors medically inappropriate. Their rheumatologist documents this contraindication explicitly rather than assuming the reviewer will infer it, and Cosentyx is approved without a step therapy trial.
Scenario: Newly diagnosed patient with no prior biologic history
A patient newly diagnosed with ankylosing spondylitis has never tried a biologic. Their provider first documents an adequate NSAID trial, since that's often the required step before any biologic — including Cosentyx — is considered on this plan's formulary, avoiding an automatic denial for skipping conventional therapy entirely.